BetterLife Highlights Advantages of Non-hallucinogenic LSD Derivative BETR-001 and Publication of its Methods to Treat Mood Disorders Patent
BetterLife Pharma (CSE: BETR / OTCQB: BETRF) has announced the publication of its patent for treating mental or mood disorders using 2-bromo-LSD (BETR-001), a non-hallucinogenic LSD derivative. The company highlights BETR-001's advantage over traditional psychedelics, as it maintains therapeutic benefits without hallucinogenic effects. This comes after the FDA's recent rejection of MDMA for PTSD treatment due to concerns about hallucinogenic drugs.
BetterLife aims for patient self-administration of BETR-001 at home for various psychiatric and neurological disorders. The company is completing IND-enabling studies and plans to start human clinical trials soon. Additionally, BetterLife has issued 4,983,699 common shares and warrants through the conversion of convertible debentures, with 2,250,000 shares and warrants issued to CEO Dr. Ahmad Doroudian.
BetterLife Pharma (CSE: BETR / OTCQB: BETRF) ha annunciato la pubblicazione del suo brevetto per il trattamento dei disturbi mentali o dell'umore utilizzando 2-bromo-LSD (BETR-001), un derivato dell'LSD non allucinogeno. L'azienda mette in evidenza il vantaggio di BETR-001 rispetto ai tradizionali psichedelici, poiché mantiene i benefici terapeutici senza effetti allucinogeni. Questo annuncio arriva dopo il recente rifiuto della FDA per l'uso dell'MDMA nel trattamento del PTSD, a causa di preoccupazioni riguardo i farmaci allucinogeni.
BetterLife punta all'auto-somministrazione di BETR-001 da parte dei pazienti a casa per vari disturbi psichiatrici e neurologici. L'azienda sta completando gli studi abilitanti IND e prevede di iniziare presto la sperimentazione clinica su esseri umani. Inoltre, BetterLife ha emesso 4.983.699 azioni comuni e warrant attraverso la conversione di obbligazioni convertibili, con 2.250.000 azioni e warrant emessi al CEO Dr. Ahmad Doroudian.
BetterLife Pharma (CSE: BETR / OTCQB: BETRF) ha anunciado la publicación de su patente para el tratamiento de trastornos mentales o del estado de ánimo utilizando 2-bromo-LSD (BETR-001), un derivado del LSD no alucinógeno. La compañía destaca la ventaja de BETR-001 sobre los psicodélicos tradicionales, ya que mantiene los beneficios terapéuticos sin efectos alucinógenos. Esto ocurre tras el reciente rechazo de la FDA al MDMA para el tratamiento del PTSD debido a preocupaciones sobre las drogas alucinógenas.
BetterLife aspira a la auto-administración de BETR-001 en casa para diversos trastornos psiquiátricos y neurológicos. La compañía está completando estudios que permiten IND y planea comenzar ensayos clínicos en humanos pronto. Además, BetterLife ha emitido 4.983.699 acciones comunes y warrants a través de la conversión de bonos convertibles, con 2.250.000 acciones y warrants emitidos al CEO Dr. Ahmad Doroudian.
BetterLife Pharma (CSE: BETR / OTCQB: BETRF)는 2-bromo-LSD (BETR-001)를 사용하여 정신 또는 기분 장애를 치료하기 위한 특허를 발표했습니다. BETR-001은 비환각성 LSD 파생물입니다. 회사는 BETR-001이 전통적인 환각제에 비해 이점을 가지고 있다고 강조하며, 이는 환각 효과 없이 치료적 효능을 유지합니다. 이는 FDA가 환각제에 대한 우려로 PTSD 치료를 위한 MDMA를 최근에 거부한 이후의 발표입니다.
BetterLife는 BETR-001의 자가 투여를 환자가 집에서 여러 정신 및 신경 장애에 대해 계획하고 있습니다. 회사는 IND 지원 연구를 완료 중에 있으며 곧 인간 임상 시험을 시작할 계획입니다. 또한, BetterLife는 전환 사채의 전환을 통해 4,983,699주 및 배당주를 발행했으며, CEO Dr. Ahmad Doroudian에게 2,250,000주와 배당주를 발행했습니다.
BetterLife Pharma (CSE: BETR / OTCQB: BETRF) a annoncé la publication de son brevet pour le traitement des troubles mentaux ou de l'humeur à l'aide de 2-bromo-LSD (BETR-001), un dérivé de LSD non hallucinogène. L'entreprise souligne l'avantage de BETR-001 par rapport aux psychédéliques traditionnels, car il maintient des bénéfices thérapeutiques sans effets hallucinogènes. Cela survient après le récent refus de la FDA concernant l'utilisation de l'MDMA pour le traitement du PTSD en raison de préoccupations concernant les drogues hallucinogènes.
BetterLife vise à permettre aux patients de s'auto-administrer BETR-001 chez eux pour divers troubles psychiatriques et neurologiques. L'entreprise termine des études préalables à l'IND et prévoit de commencer prochainement des essais cliniques sur l'homme. De plus, BetterLife a émis 4.983.699 actions ordinaires et bons de souscription par la conversion d'obligations convertibles, avec 2.250.000 actions et bons de souscription émis au PDG Dr. Ahmad Doroudian.
BetterLife Pharma (CSE: BETR / OTCQB: BETRF) hat die Veröffentlichung seines Patents zur Behandlung von psychischen oder Stimmungserkrankungen mithilfe von 2-Bromo-LSD (BETR-001), einem nicht-halluzinogenen LSD-Derivat, bekannt gegeben. Das Unternehmen hebt den Vorteil von BETR-001 im Vergleich zu traditionellen Psychedelika hervor, da es therapeutische Vorteile ohne halluzinogene Effekte bietet. Dies folgt auf die jüngste Ablehnung von MDMA durch die FDA zur Behandlung von PTSD aufgrund von Bedenken hinsichtlich halluzinogener Drogen.
BetterLife strebt die Selbstverabreichung von BETR-001 zu Hause für verschiedene psychiatrische und neurologische Störungen an. Das Unternehmen schließt derzeit IND-erlaubende Studien ab und plant, bald klinische Studien an Menschen zu beginnen. Darüber hinaus hat BetterLife 4.983.699 Stammaktien und Bezugsrechte durch die Umwandlung von wandelbaren Anleihen ausgegeben, wobei 2.250.000 Aktien und Bezugsrechte an den CEO Dr. Ahmad Doroudian ausgegeben wurden.
- Publication of patent for treating mental or mood disorders using BETR-001
- BETR-001 maintains therapeutic benefits of LSD without hallucinogenic effects
- Potential for patient self-administration at home, avoiding need for specialized clinics
- Completion of IND-enabling studies and planned start of human clinical trials
- Issuance of 4,983,699 common shares and warrants, potentially diluting existing shareholders
VANCOUVER, British Columbia, Aug. 27, 2024 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development of 2-bromo-LSD (BETR-001), a non-hallucinogenic derivative of lysergic acid diethylamide (“LSD”), today announced the publication of its patent entitled “Methods of treating mental or mood disorders using 2-bromo-LSD” (Publication No. US-2024-0058326-A1) by the United States Patent and Trademarks Office.
Dr. Ahmad Doroudian, CEO of BetterLife, commented, “The tremendous advantage of BETR-001 is its fully non-hallucinogenic property, while maintaining robust activity in animal depression and anxiety models. Earlier this month, the US FDA rejected the NDA for the hallucinogen MDMA for the treatment of PTSD. In its decision, the FDA echoed the concerns raised in June 2024 by its Advisory Committee which recommended the rejection of the application. These issues are not isolated to MDMA but face all first and second generation psychedelics, including the need for specialized clinics and having strict controlled substance classification.”
Dr. Doroudian added, “In contrast to first and second generation psychedelics, BETR-001 is non-hallucinogenic. We believe BETR-001 will deliver all the therapeutic benefits of LSD without the burden of being hallucinogenic. Our goal is patient self-administration of BETR-001 at home for the treatment of various psychiatric and neurological disorders.”
BetterLife is currently completing BETR-001 IND-enabling studies, and projects to file the BETR-001 IND and start human clinical trials upon the completion of the studies.
The Company also announces that it has issued 4,983,699 common shares and 4,983,699 share purchase warrants pursuant to the conversion option of convertible debentures and accrued interest on convertible debentures totalling
About BetterLife Pharma
BetterLife Pharma Inc. is an emerging biotechnology company primarily focused on developing and commercializing two compounds, BETR-001 and BETR-002, to treat neuro-psychiatric and neurological disorders.
BETR-001, which is in preclinical and IND-enabling studies, is a non-hallucinogenic and non-controlled LSD derivative in development and it is unique in that it is unregulated and therefore can be self-administered. BetterLife’s synthesis patent for BETR-001 eliminates regulatory hurdles and its pending patent, for composition and method of use, covers treatment of major depressive disorder, anxiety disorder and neuropathic pain and other neuro-psychiatric and neurological disorders.
BETR-002, which is in preclinical and IND-enabling studies, is based on honokiol, the active anxiolytic ingredient of magnolia bark. BetterLife’s pending method of use and formulations patent covers treatment of anxiety related disorders including benzodiazepine dependency.
BetterLife also owns a drug candidate for the treatment of viral infections and is in the process of seeking strategic alternatives for further development.
For further information, please visit BetterLife Pharma.
Contact
David Melles, Investor Relations Manager
Email: David.Melles@blifepharma.com
Phone: 1-778-887-1928
Cautionary Note Regarding Forward-Looking Statements
No securities exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.
FAQ
What is the main advantage of BetterLife's BETR-001 over traditional psychedelics?
When does BetterLife (BETRF) plan to start human clinical trials for BETR-001?
How many shares and warrants did BetterLife (BETRF) issue on August 27, 2024?
What is the exercise price and expiration date for the warrants issued by BetterLife (BETRF)?
